Toripalimab/Chemotherapy Combo Improves Outcomes in Small Cell Lung Cancer
Toripalimab added to etoposide plus cisplatin or carboplatin improved survival in extensive-stage small cell lung cancer.
Read MoreOct 27, 2023
Toripalimab added to etoposide plus cisplatin or carboplatin improved survival in extensive-stage small cell lung cancer.
Read MoreOct 27, 2023
Pembrolizumab plus neoadjuvant chemotherapy in early-stage, high-risk ER+/HER2- breast cancer leads to a statistically significant increase in pathological complete response.
Read MoreOct 27, 2023
Nivolumab/relatlimab neoadjuvant treatment of deficient mismatch repair colon cancer shows impressive pathological response rates.
Read MoreOct 27, 2023
First-line enfortumab vedotin (EV) plus pembrolizumab significantly improved survival in patients with locally advanced or metastatic urothelial cancer.
Read MoreOct 26, 2023
The healthcare arena’s figurative boxing match between physicians and nurses over who besides...
Read MoreOct 26, 2023
One-time lifileucel induces a strong and durable response in patients with advanced mucosal melanoma.
Read MoreOct 26, 2023
Perioperative chemotherapy plus nivolumab outperforms perioperative chemotherapy alone in patients with resectable non-small cell lung cancer.
Read MoreOct 26, 2023
Enzalutamide plus LuPSMA has enhanced anticancer effects in prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.
Read MoreOct 26, 2023
Most infants admitted to the ICU with RSV do not have an underlying medical condition, but RSV remains a top cause of hospitalization in the first year of life.
Read MoreOct 26, 2023
Generative AI technology may transform healthcare delivery and life sciences productivity by improving patient outcomes and increasing clinical and medical research efficiency.
Read MoreOct 25, 2023
Durvalumab added to chemotherapy improves pathological complete response rate in the perioperative setting for patients with gastric cancer.
Read MoreOct 25, 2023
Atezolizumab plus chemotherapy and maintenance niraparib in late-relapsing recurrent chemotherapy-sensitive ovarian cancer does not significantly improve outcomes.
Read MoreOct 25, 2023
Pembrolizumab added to neoadjuvant and adjuvant chemotherapy improves event-free survival in patients with early triple-negative breast cancer (TNBC).
Read MoreOct 25, 2023
Explore, connect, learn, relax and more at the AAO 2023 Expo. Follow PW for conference updates.
Read MoreOct 25, 2023
AAO Announces The Orbital 2023: Gold Rush Fundraising Event, formerly the Orbital Gala.
Read MoreOct 25, 2023
Hispanic people have a disproportionately high incidence of liver cancer compared with other groups but are under-represented in Phase 3 trials for the disease.
Read MoreOct 24, 2023
The growing number of physicians approaching retirement age face a plethora of misinformation pertaining to retirement planning.
Read MoreOct 24, 2023
Researchers report higher PrEP use and fewer insurance-related issues from 2019 to 2021, but the Braidwood versus Becerra case could impact these improvements.
Read MoreOct 23, 2023
Physicians typically address movement disorders, such as tardive dyskinesia, during in-person examinations; however, a recent study shows that telehealth visits can be a part of treatment plans.
Read MoreOct 23, 2023
Providing psychoeducation throughout recovery and rehabilitation from burn injuries may offer opportunities to facilitate access to psychological support.
Read More